Rather, when liver tumorigenesis is in progress, GSH supplementation reduces intracellular ROS levels and desensitizes the Nrf2/GCLC antioxidant signaling pathway, thus increasing the incidence of HCC [9]. This evidence concerns the gene GCLC and hepatocellular carcinoma.